Asia-Pacific Lupus Collaborative’s low-disease activity score can predict risk of flare-ups, according to research from a group at Hong Kong University.
All articles by Drew Amorosi
Study of patients with systemic lupus erythematosus in China evaluates quality of life measures in several areas.
Study examines the predictive value for vertebral fractures of bone mineral density and bone turnover markers after a 5-year drug holiday.
A small study from Romania evaluated whether the presence of osteoarthritis had an effect on the parameters used to evaluate disease activity in patients with early rheumatoid arthritis.
American College of Rheumatology provides mixed opinions on the proposed American Health Care Act.
Responses come after House leadership introduces the American Health Care Act, the proposed replacement for Obamacare.
Study evaluated clinical data to determine a possible role of major depressive disorders in the progression of inflammatory disease.
Median levels of 24 elements were assessed in patients with systemic sclerosis and matched controls.
A European committee of pediatric rheumatology experts has provided the first consensus-based recommendations for clinical management of juvenile dermatomyositis.
The Lupus Foundation of America is now accepting applications for 8 grants, with dedicated awards to minority applicants, pediatric research, and research that has an impact on rural areas.
Study finds weak evidence for using biomarkers as a guide to tapering or discontinuing biologic therapy in patients with rheumatoid arthritis.
The FDA has given its approval for 26-week treatment efficacy claims for Zimmer Biomet’s knee osteoarthritis product.
Patient care is more than providing treatment and measuring disease activity, says Jonathan Krant, MD, a rheumatologist from upstate New York. In this interview, the chief of medicine for the Adirondack Health System explains the disconnect between what physicians would like to learn from their patients and what their time constraints allow.
Regulator advises use of unique suffix system to identify each biological product and biosimilars.
FDA will fast track review of nonsteroidal treatment option for giant cell arteritis.
American and European experts forge first commonly accepted and validated classification criteria for Sjögren syndrome.
Letter to Congress outlines the needs of patients with rheumatic diseases and the importance of early access to specialty care.
Study examines the effect of TNFi therapy on inflammation and its ability to reduce the incidence of myocardial infarction.
The 115th US Congress is wasting no time considering reforms to the outgoing president’s signature healthcare legislation.
EULAR revised its recommendations for management of early arthritis, including faster referral to specialists from onset of symptoms.
The sBLAs included data from two Phase 3 studies that assessed the safety and efficacy of Simponi Aria 2mg/kg infusion every 8 weeks after two starter doses at Weeks 0 and 4 in adults with active psoriatic arthritis.
A review and analysis of registry data from patients with RA indicates that changing from rituximab to another class of biologic agent does not alter the subsequent risk of infection.
A retrospective analysis has shown that patients with ANCA-associated vasculitis treated with rituximab have a much lower risk of developing subsequent malignancies when compared with those treated with cyclophosphamide.